Literature DB >> 25070981

Ovarian xenobiotic biotransformation enzymes are altered during phosphoramide mustard-induced ovotoxicity.

Jill A Madden1, Aileen F Keating2.   

Abstract

The anti-neoplastic prodrug, cyclophosphamide, requires biotransformation to phosphoramide mustard (PM), which partitions to volatile chloroethylaziridine (CEZ). PM and CEZ are ovotoxicants, however their ovarian biotransformation remains ill-defined. This study investigated PM and CEZ metabolism mechanisms through the utilization of cultured postnatal day 4 (PND4) Fisher 344 (F344) rat ovaries exposed to vehicle control (1% dimethyl sulfoxide (DMSO)) or PM (60μM) for 2 or 4 days. Quantification of mRNA levels via an RT(2) profiler PCR array and target-specific RT-PCR along with Western blotting found increased mRNA and protein levels of xenobiotic metabolism genes including microsomal epoxide hydrolase (Ephx1) and glutathione S-transferase isoform pi (Gstp). PND4 ovaries were treated with 1% DMSO, PM (60μM), cyclohexene oxide to inhibit EPHX1 (CHO; 2mM), or PM + CHO for 4 days. Lack of functional EPHX1 increased PM-induced ovotoxicity, suggesting a detoxification role for EPHX1. PND4 ovaries were also treated with 1% DMSO, PM (60μM), BSO (Glutathione (GSH) depletion; 100μM), GEE (GSH supplementation; 2.5mM), PM ± BSO, or PM ± GEE for 4 days. GSH supplementation prevented PM-induced follicle loss, whereas no impact of GSH depletion was observed. Lastly, the effect of ovarian GSH on CEZ liberation and ovotoxicity was evaluated. Both untreated and GEE-treated PND4 ovaries were plated adjacent to ovaries receiving PM + GEE or PM + BSO treatments. Less CEZ-induced ovotoxicity was observed with both GEE and BSO treatments indicating reduced CEZ liberation from PM. Collectively, this study supports ovarian biotransformation of PM, thereby influencing the ovotoxicity that ensues.
© The Author 2014. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  chemotherapy; glutathione; metabolism; ovary

Mesh:

Substances:

Year:  2014        PMID: 25070981      PMCID: PMC4271048          DOI: 10.1093/toxsci/kfu146

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  38 in total

1.  A new mathematical model for relative quantification in real-time RT-PCR.

Authors:  M W Pfaffl
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Characterization of a rat in vitro ovarian culture system to study the ovarian toxicant 4-vinylcyclohexene diepoxide.

Authors:  Patrick J Devine; I Glenn Sipes; Michael K Skinner; Patricia B Hoyer
Journal:  Toxicol Appl Pharmacol       Date:  2002-10-15       Impact factor: 4.219

4.  Studies on enzymatic hydrolysis of aziridines. II. Stereoselective hydrolysis of N-substituted 28,38-imino-5 -cholestanes by hepatic microsomal aziridine hydrolase.

Authors:  T Watabe; S Suzuki
Journal:  Biochem Biophys Res Commun       Date:  1972-02-16       Impact factor: 3.575

5.  [A volatile alkylating agent in the exhaled air following the administration of Endoxan].

Authors:  H M Rauen; K Norpoth
Journal:  Klin Wochenschr       Date:  1968-03-01

6.  Glutathione (GSH) concentrations vary with the cell cycle in maturing hamster oocytes, zygotes, and pre-implantation stage embryos.

Authors:  Kurt A Zuelke; Susan C Jeffay; Robert M Zucker; Sally D Perreault
Journal:  Mol Reprod Dev       Date:  2003-01       Impact factor: 2.609

7.  Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide.

Authors:  J L Flowers; S M Ludeman; M P Gamcsik; O M Colvin; K L Shao; J H Boal; J B Springer; D J Adams
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

Review 8.  The chemistry of the metabolites of cyclophosphamide.

Authors:  S M Ludeman
Journal:  Curr Pharm Des       Date:  1999-08       Impact factor: 3.116

Review 9.  Cyclophosphamide for treating rheumatoid arthritis.

Authors:  M E Suarez-Almazor; E Belseck; B Shea; G Wells; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2000

10.  Expression and activity of microsomal epoxide hydrolase in follicles isolated from mouse ovaries.

Authors:  Ellen A Cannady; Cheryl A Dyer; Patricia J Christian; I Glenn Sipes; Patricia B Hoyer
Journal:  Toxicol Sci       Date:  2002-07       Impact factor: 4.849

View more
  5 in total

1.  Obesity alters phosphoramide mustard-induced ovarian DNA repair in mice.

Authors:  Shanthi Ganesan; Jackson Nteeba; Jill A Madden; Aileen F Keating
Journal:  Biol Reprod       Date:  2017-02-01       Impact factor: 4.285

2.  The Natural Carotenoid Crocetin and the Synthetic Tellurium Compound AS101 Protect the Ovary against Cyclophosphamide by Modulating SIRT1 and Mitochondrial Markers.

Authors:  Giovanna Di Emidio; Giulia Rossi; Isabelle Bonomo; Gonzalo Luis Alonso; Roberta Sferra; Antonella Vetuschi; Paolo Giovanni Artini; Alessandro Provenzani; Stefano Falone; Gaspare Carta; Anna Maria D'Alessandro; Fernanda Amicarelli; Carla Tatone
Journal:  Oxid Med Cell Longev       Date:  2017-11-15       Impact factor: 6.543

Review 3.  Ovarian damage from chemotherapy and current approaches to its protection.

Authors:  N Spears; F Lopes; A Stefansdottir; V Rossi; M De Felici; R A Anderson; F G Klinger
Journal:  Hum Reprod Update       Date:  2019-11-05       Impact factor: 15.610

4.  Extended adverse effects of cyclophosphamide on mouse ovarian function.

Authors:  Jihyun Kim; Sooseong You
Journal:  BMC Pharmacol Toxicol       Date:  2021-01-07       Impact factor: 2.483

5.  Protective effects of a SIRT1 inhibitor on primordial follicle activation and growth induced by cyclophosphamide: insights from a bovine in vitro folliculogenesis system.

Authors:  Giovanna Di Emidio; Carla Tatone; Vincenza Barbato; Vincenzo Genovese; Martina Placidi; Riccardo Talevi; Roberto Gualtieri
Journal:  J Assist Reprod Genet       Date:  2022-03-05       Impact factor: 3.357

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.